Background. Granulocyte colony stimulating factor (G-CSF) safely stimulates the production of neutrophils in normal people and neutropenic patients. Phase II studies have been completed that explored the role of G-CSF in either abrogating or accelerating recovery from chemotherapy-induced neutropenia. Methods. Fourteen patients with resistant/relapsed high-grade non-Hodgkin's lymphoma were treated with a dexamethasone, cytarabine and cisplatin (DHAP) regimen, and with G-CSF between chemotherapeutic courses. Results. All patients showed a rise in neutrophil count; none was neutropenic when hospitalized for subsequent DHAP courses. Furthermore, the interval between cycles was decreased in 11 of the 14 patients. The overall response rate was 86%, with 4 patients obtaining complete remission. Conclusions. Administration of G-CSF was associated with an acceleration of neutrophil recovery, indicating its potential to reduce the risk of infection and to maintain planned chemotherapy doses.
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) AS ADJUNCT THERAPY IN RELAPSED-RESISTANT HIGH-GRADE NON-HODGKINS-LYMPHOMA / P. L., Zinzani; Martelli, Maurizio; S., Tura; Mandelli, Franco. - In: HAEMATOLOGICA. - ISSN 0390-6078. - STAMPA. - 78:1(1993), pp. 40-43.
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) AS ADJUNCT THERAPY IN RELAPSED-RESISTANT HIGH-GRADE NON-HODGKINS-LYMPHOMA
MARTELLI, Maurizio;MANDELLI, Franco
1993
Abstract
Background. Granulocyte colony stimulating factor (G-CSF) safely stimulates the production of neutrophils in normal people and neutropenic patients. Phase II studies have been completed that explored the role of G-CSF in either abrogating or accelerating recovery from chemotherapy-induced neutropenia. Methods. Fourteen patients with resistant/relapsed high-grade non-Hodgkin's lymphoma were treated with a dexamethasone, cytarabine and cisplatin (DHAP) regimen, and with G-CSF between chemotherapeutic courses. Results. All patients showed a rise in neutrophil count; none was neutropenic when hospitalized for subsequent DHAP courses. Furthermore, the interval between cycles was decreased in 11 of the 14 patients. The overall response rate was 86%, with 4 patients obtaining complete remission. Conclusions. Administration of G-CSF was associated with an acceleration of neutrophil recovery, indicating its potential to reduce the risk of infection and to maintain planned chemotherapy doses.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.